Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H (HK:0874)
:0874
Want to see HK:0874 full AI Analyst Report?
0874 Stock Chart & Stats
HK$18.75
-HK$0.10(-0.58%)
At close: 4:00 PM EST
HK$18.75
-HK$0.10(-0.58%)
Day’s Range― - ―
52-Week RangeHK$16.47 - HK$20.40
Previous CloseN/A
Volume792.44K
Average Volume (3M)908.48K
Market Cap
HK$39.99B
Enterprise ValueHK$43.63B
Total Cash (Recent Filing)HK$12.29B
Total Debt (Recent Filing)HK$18.57B
Price to Earnings (P/E)8.9
Beta0.65
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.15%
Share Statistics
EPS (TTM)1.26
Shares Outstanding219,900,000
10 Day Avg. Volume928,235
30 Day Avg. Volume908,476
Financial Highlights & Ratios
PEG Ratio3.10
Price to Book (P/B)0.68
Price to Sales (P/S)0.34
P/FCF Ratio-27.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.99
Revenue Forecast (FY)HK$82.57B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthTTM revenue up ~77% reflects sustained demand and successful distribution of core products across channels. Durable top-line expansion increases scale, supports longer-term investment in R&D and distribution, and provides a platform to recover margins if cost control improves.
Diversified Business ModelMultiple segments—proprietary TCM, Western drugs, and wholesale/retail distribution—reduce dependence on any single product or channel. This structural diversification smooths revenue volatility, enables cross-selling, and preserves resilience to product-specific or tendering shocks over the medium term.
Moderate Leverage With Equity GrowthBalance sheet shows moderate leverage and rising equity, providing capacity to fund working capital or selective investments without extreme strain. Equity growth increases loss-absorbing capacity and supports strategic flexibility, helping manage medium-term funding needs amid cyclical pressures.
Bears Say
Weak Cash GenerationThe swing to negative FCF in 2025 and only modest positive TTM FCF signals deteriorating cash conversion. This reduces internal funding for capex, R&D, and dividends, increases reliance on external financing, and raises earnings-quality risk that can constrain strategy over multiple quarters.
Margin CompressionSubstantially lower EBIT and net margins despite strong sales growth suggest adverse mix, pricing pressure, or rising costs. Persistent margin erosion undermines sustainable profitability and free cash flow generation, limiting reinvestment capacity and making the business more vulnerable to cost shocks.
Rising Leverage And Weaker ROEA meaningful rise in debt-to-equity alongside falling ROE indicates less efficient capital use and higher financial risk. Higher leverage increases interest and refinancing sensitivity, potentially restricting strategic options and elevating downside risk across the next several quarters.
Guangzhou Baiyunshan Pharmaceutical Holdings Company News
0874 FAQ
What was Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price range in the past 12 months?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H lowest stock price was HK$16.47 and its highest was HK$20.40 in the past 12 months.
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap is HK$39.99B.
When is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date is Aug 13, 2026 which is in 106 days.
How were Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s earnings last quarter?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H released its earnings results on Apr 27, 2026. The company reported HK$1.26 earnings per share for the quarter, beating the consensus estimate of N/A by HK$1.26.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H overvalued?
According to Wall Street analysts Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price is currently Overvalued.
Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pay dividends?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pays a Quarterly dividend of HK$0.44 which represents an annual dividend yield of 7.15%. See more information on Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H dividends here
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H have?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H has 219,900,000 shares outstanding.
What happened to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price movement after its last earnings report?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H reported an EPS of HK$1.26 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H?
Currently, no hedge funds are holding shares in HK:0874
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.34%
12-Months-Change
Fundamentals
Return on Equity
7.89%
Trailing 12-Months
Asset Growth
8.07%
Trailing 12-Months
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) Earnings & Revenues
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---